This Article Full Text Full Text (PDF) All Versions of this Article: 118/3/238    most recent CIRCULATIONAHA.107.756544v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Google Scholar Articles by Heidecker, B. Articles by Hare, J. M. PubMed PubMed Citation Articles by Heidecker, B. Articles by Hare, J. M. Related Collections Clinical genetics Other heart failure Congestive Gene therapy Genetics of cardiovascular disease Gene expression Genomics Heart failure - basic studies Physiological and pathological control of gene expression Related Article

(Circulation. 2008;118:238-246.)
© 2008 American Heart Association, Inc.

Heart Failure

Transcriptomic Biomarkers for Individual Risk Assessment in New-Onset Heart Failure

Bettina Heidecker, MD; Edward K. Kasper, MD; Ilan S. Wittstein, MD; Hunter C. Champion, MD, PhD; Elayne Breton, RN; Stuart D. Russell, MD; Michelle M. Kittleson, MD, PhD; Kenneth L. Baughman, MD; Joshua M. Hare, MD

From the University of Miami (B.H., J.M.H.), Miller School of Medicine, Miami, Fla; The Johns Hopkins Hospital (E.K.K., I.S.W., H.C.C., E.B., S.D.R.), Baltimore, Md; University of California, Los Angeles (M.M.K.); and Brigham and Women’s Hospital (K.L.B.), Boston, Mass.

Correspondence to Joshua M. Hare, MD, Miller School of Medicine, University of Miami Division of Cardiology, CRB, 1120 NW 14th St, Suite 1124, Miami, FL 33136. E-mail jhare{at}med.miami.edu

Received December 3, 2007; accepted April 28, 2008.

Background— Prediction of prognosis remains a major unmet need in new-onset heart failure (HF). Although several clinical tests are in use, none accurately distinguish between patients with poor versus excellent survival. We hypothesized that a transcriptomic signature, generated from a single endomyocardial biopsy, could serve as a novel prognostic biomarker in HF.

Methods and Results— Endomyocardial biopsy samples and clinical data were collected from all patients presenting with new-onset HF from 1997 to 2006. Among a total of 350 endomyocardial biopsy samples, 180 were identified as idiopathic dilated cardiomyopathy. Patients with phenotypic extremes in survival were selected: good prognosis (event-free survival for at least 5 years; n=25) and poor prognosis (events [death, requirement for left ventricular assist device, or cardiac transplant] within the first 2 years of presentation with HF symptoms; n=18). We used human U133 Plus 2.0 microarrays (Affymetrix) and analyzed the data with significance analysis of microarrays and prediction analysis of microarrays. We identified 46 overexpressed genes in patients with good versus poor prognosis, of which 45 genes were selected by prediction analysis of microarrays for prediction of prognosis in a train set (n=29) with subsequent validation in test sets (n=14 each). The biomarker performed with 74% sensitivity (95% CI 69% to 79%) and 90% specificity (95% CI 87% to 93%) after 50 random partitions.

Conclusions— These findings suggest the potential of transcriptomic biomarkers to predict prognosis in patients with new-onset HF from a single endomyocardial biopsy sample. In addition, our findings offer potential novel therapeutic targets for HF and cardiomyopathy.

---

 

CLINICAL PERSPECTIVE

Related Article:

Clinical Summaries
Circulation 2008 118: 211-212. [Full Text]

This article has been cited by other articles:

				G. W. Dorn II and S. J. Matkovich Put Your Chips on Transcriptomics Circulation, July 15, 2008; 118(3): 216 - 218. [Full Text] [PDF]